dry AMD stem cells

Brief update from Bob Lanza on Astellas stem cell program

Lanza-Astellas

Late in 2015, one of the pioneering stem cell and regenerative medicine biotechs, Ocata Therapeutics (fka as ACT or Advanced Cell Technology) was acquired by Astellas Pharma. At the time of purchase, Ocata had a number of areas of focus, but was most closely followed for its development of human embryonic stem cell-based retinal pigmented epithelial …

Brief update from Bob Lanza on Astellas stem cell program Read More »

Stem cell news bites: Mesoblast, BioTime, MS, FDA Warning, & More

Mesoblast-stock

Stem cell studies continue to make big news with a mixed bag of trends, and some good stem cell news and others not so much. Mesoblast ($MESO) had its stock suspended for quite so time recently in anticipation of a big announcement. When that news came today it was discouraging in the form of its partner …

Stem cell news bites: Mesoblast, BioTime, MS, FDA Warning, & More Read More »

Masayo Takahashi (高橋 政代) on IPSC Trial for Vision

Monkey-stem-cell-RPEs

Masayo Takahashi (高橋 政代) on IPSC Trial for Macular Degeneration By Michael Cea Stem Cell Analyst & Advocate (editor’s note: piece was originally posted on Michael’s blog here; follow Michael on Twitter @msemporda) Having followed closely the developments in programs using pluripotent based therapeutics I was fortunate during ISSCR2015 to have the opportunity to sit down with …

Masayo Takahashi (高橋 政代) on IPSC Trial for Vision Read More »